GSK resolves patent lawsuit against Pfizer over RSV vaccines
By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
Pharmaceutical Technology on MSN2d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSK
Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
Zacks.com on MSN1d
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Pfizer announces European Commission approval of Abrysvo indication extension
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna
Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...
Pfizer reports EC approval of amending marketing authorization of Abrysvo
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Pfizer Gets Expanded European Approval of Abrysvo RSV Vaccine for All Adults
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Mirage News2d
EU Approves Pfizer's ABRYSVO RSV Vaccine for Adults 18-59
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO®, the ...
Pharmabiz2d
Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease
Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...